News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Feb 24, 2020
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant SystemFeb 10, 2020
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected PatientsJan 28, 2020
Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Coronavirus (2019-nCoV)Jan 10, 2020
Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant Pleural Effusions (MPE)Dec 30, 2019
Clover Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in ChinaNov 28, 2019
Clover Completes $43 Million Series B FinancingNov 21, 2019
Clover Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)Sep 29, 2019
Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant AscitesSep 10, 2019
Clover Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal CarcinomatosisMay 07, 2019
Clover Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China
